ResMed Inc (BSP:R1MD34)
R$ 381 9.84 (2.65%) Market Cap: 223.72 Bil Enterprise Value: 226.25 Bil PE Ratio: 32.98 PB Ratio: 7.04 GF Score: 86/100

Resmed Inc at KeyBanc Capital Markets Life Sciences & MedTech Forum (Virtual) Transcript

Mar 22, 2022 / 05:30PM GMT
Release Date Price: R$306.86
Matthew Ian Mishan
KeyBanc Capital Markets Inc., Research Division - VP & Senior Equity Research Analyst

Good afternoon. I'd like to welcome everyone to the first day of the KeyBank Life Sciences MedTech & Investor Forum. My name is Matt Mishan. I'm a senior at MedTech Analyst, and I'm pleased to be joined by ResMed, which is represented today by its CEO, Mick Farrell.

Questions & Answers

Matthew Ian Mishan
KeyBanc Capital Markets Inc., Research Division - VP & Senior Equity Research Analyst

For the audience, I'll start us off, but questions can be submitted directly to me by typing into the box below the video screen, and I can relay.

So Mick, welcome. Thank you for joining us. I'm just going to get right to it and ask how should we think about the Russia-Ukraine and the COVID shutdowns in Asia impacting your ability to kind of ramp supply chain at this point?

Michael J. Farrell
ResMed Inc. - CEO & Director

Yes. Well, look, there are a bunch of factors in the market right now,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot